Vertex Pharmaceuticals Incorporated (ETR:VX1)
391.85
+0.45 (0.11%)
May 13, 2025, 5:35 PM CET
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.77B USD in the quarter ending March 31, 2025, with 2.96% growth. This brings the company's revenue in the last twelve months to $11.10B, up 8.98% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.10B
Revenue Growth
+8.98%
P/S Ratio
9.88
Revenue / Employee
$1.82M
Employees
6,100
Market Cap
101.47B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Merck KGaA | 21.16B |
Siemens Healthineers AG | 23.14B |
Fresenius SE & Co. KGaA | 22.13B |
Bayer Aktiengesellschaft | 46.61B |
Fresenius Medical Care AG | 19.49B |
Sartorius Aktiengesellschaft | 3.44B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.33B |
Vertex Pharmaceuticals News
- 2 days ago - Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio? - Benzinga
- 4 days ago - Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
- 6 days ago - Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - Seeking Alpha
- 6 days ago - SA analyst upgrades: TSLA, MSFT, AMD, PLTR, VRTX, ONON, CB - Seeking Alpha
- 6 days ago - Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - The Motley Fool
- 6 days ago - Vertex On Track To Significantly Improve Revenue And Earnings By 2030 - Seeking Alpha
- 7 days ago - Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Benzinga
- 7 days ago - Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Benzinga